Dynavax Technologies Number of Employees 2010-2022 | DVAX

Dynavax Technologies number of employees from 2010 to 2022. Number of employees can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures, expressed on a per share basis
Dynavax Technologies Annual Number of Employees
2021 311
2020 245
2019 231
2018 249
2017 170
2016 251
2015 234
2014 197
2013 151
2012 167
2011 150
2010 128
2009 130
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.616B $0.439B
Dynavax Technologies discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Dynavax's clinical development programs are based on immunostimulatory sequences which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $166.663B 10.14
Bio-Rad Laboratories (BIO.B) United States $14.121B 30.63
QIAGEN (QGEN) Netherlands $10.600B 16.73
Biohaven Pharmaceutical Holding (BHVN) United States $10.272B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.442B 0.00
Arcus Biosciences (RCUS) United States $1.751B 44.38
Emergent Biosolutions (EBS) United States $1.534B 6.57
Myovant Sciences (MYOV) United Kingdom $1.224B 0.00
Zymeworks (ZYME) Canada $0.317B 0.00
Gelesis Holdings (GLS) United States $0.111B 0.00
Ambrx Biopharma (AMAM) United States $0.100B 0.00
Enzo Biochem (ENZ) United States $0.097B 0.00
SQZ Biotechnologies (SQZ) United States $0.089B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00